Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Most patients with appendix cancer may avoid chemotherapy after surgery, study suggests (opens in a new tab)

medicalxpress.com · 2026-09-09

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. 2 other points were not covered by the paper.

  • 6 supported
  • 1 overstated
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Six of nine check out. Two claims the study doesn't address.

  • 6 supported
  • 1 overstated
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

9 claims in this story

Showing all 9 claimsChoose a verdict to focus the list.

Claim 1 of 9OverstatedMost patients with localized appendix cancer may be able to safely avoid chemotherapy after surgery, according to a new study from researchers at The University of Texas MD Anderson Cancer Center.View evidenceHide evidence

As statedmost patients

Why this verdict

The paper profile supports that relapse was uncommon after resection and that adjuvant chemotherapy was not associated with improved RFS or OS in multivariable observational analyses. However, the headline framing that most patients may be able to 'safely avoid' chemotherapy turns a retrospective, nonrandomized association into a clinical safety/treatment-avoidance implication. The headline therefore outruns the evidentiary strength of the body-level association.

1

Study evidence

Relapse after resection was uncommon in the institutional surgical subset (19 of 202; 9.4%); relapse rates by stage were 6% for stage II and 19.5% for stage III.9.4% overall relapse in surgical subset; stage II 6%; stage III 19.5%

“This retrospective cohort study (January 2000 through February 2024; median follow-up, 62.6 months) used Kaplan-Meier and Cox proportional hazards modeling.”
2

Study evidence

In the complete localized cohort, adjuvant chemotherapy was not associated with improved recurrence-free survival after multivariable adjustment.Multivariable HR for RFS 0.98 (95% CI, 0.43–2.28; P = .90); Univariable HR 2.06 (95% CI, 1.36–3.13; P = .001).

“EXPOSURES: Surgical resection with or without adjuvant chemotherapy.”
Claim 2 of 9Not coveredThe study found that fewer than 10% of patients experienced recurrence after surgery, and chemotherapy given after surgery was not associated with improved survival or a lower risk of relapse, even among patients considered higher risk.View evidenceHide evidence

As statedfewer than 10%

Why this verdict

The abstract-level profile supports the recurrence figure under 10% in the surgical subset and supports that adjuvant chemotherapy was not associated with improved RFS or OS after multivariable adjustment. But the added claim that this held 'even among patients considered higher risk' is not documented in the supplied abstract-level profile, which does not provide high-risk subgroup chemotherapy results.

1

Study evidence

Relapse after resection was uncommon in the institutional surgical subset (19 of 202; 9.4%); relapse rates by stage were 6% for stage II and 19.5% for stage III.9.4% overall relapse in surgical subset; stage II 6%; stage III 19.5%

“This retrospective cohort study (January 2000 through February 2024; median follow-up, 62.6 months) used Kaplan-Meier and Cox proportional hazards modeling.”
2

Study evidence

In the complete localized cohort, adjuvant chemotherapy was not associated with improved recurrence-free survival after multivariable adjustment.Multivariable HR for RFS 0.98 (95% CI, 0.43–2.28; P = .90); Univariable HR 2.06 (95% CI, 1.36–3.13; P = .001).

“EXPOSURES: Surgical resection with or without adjuvant chemotherapy.”
Claim 3 of 9Not coveredThe analysis, led by John Paul Shen and Sacha El Khoury, is described as the largest study to date of localized appendix cancer and was published in JAMA Surgery.View evidenceHide evidence

As statedlargest study to date

Why this verdict

The supplied abstract-level paper profile does not include lead-author information, journal publication metadata, or evidence comparing this cohort with all prior studies to substantiate 'largest study to date.' The cohort size is reported elsewhere in the profile, but the comparative superlative and publication details are not verifiable from the supplied profile.

Claim 4 of 9SupportedResearchers also identified specific tumor characteristics and genomic alterations that may help doctors better predict which patients are most likely to see their cancer return.View evidenceHide evidence

Why this verdict

The profile reports that histopathologic subtype, pathologic T4, and selected genomic alterations were associated with relapse risk, and that molecular profiling plus histopathologic subtype refine relapse risk. The story frames this as a hedged prediction/risk-stratification possibility, which matches the observational evidence.

1

Study evidence

Relapse after resection was uncommon in the institutional surgical subset (19 of 202; 9.4%); relapse rates by stage were 6% for stage II and 19.5% for stage III.9.4% overall relapse in surgical subset; stage II 6%; stage III 19.5%

“This retrospective cohort study (January 2000 through February 2024; median follow-up, 62.6 months) used Kaplan-Meier and Cox proportional hazards modeling.”
2

Study evidence

TP53 mutation in goblet cell tumors was associated with greater risk of relapse.HR 6.93 (95% CI, 1.50–31.00); P = .01

“TP53 mutation in goblet cell tumors… and GNAS mutation in nongoblet tumors… were associated with greater risk of relapse.”
Claim 5 of 9SupportedThe researchers reviewed outcomes for 439 patients with stages 1–3 appendix cancer treated at UT MD Anderson between 2000 and 2024, and evaluated recurrence among 202 patients who underwent surgery.View evidenceHide evidence

As stated439 patients; 202 patients

Why this verdict

The profile states that the complete localized cohort included 439 patients with stage I–III appendiceal adenocarcinoma at UT MD Anderson from 2000 to 2024, and that 202 underwent surgery at UT MD Anderson for the surgical subset used for recurrence analyses.

1

Study evidence

Relapse after resection was uncommon in the institutional surgical subset (19 of 202; 9.4%); relapse rates by stage were 6% for stage II and 19.5% for stage III.9.4% overall relapse in surgical subset; stage II 6%; stage III 19.5%

“This retrospective cohort study (January 2000 through February 2024; median follow-up, 62.6 months) used Kaplan-Meier and Cox proportional hazards modeling.”
2

Study evidence

In the complete localized cohort, adjuvant chemotherapy was not associated with improved recurrence-free survival after multivariable adjustment.Multivariable HR for RFS 0.98 (95% CI, 0.43–2.28; P = .90); Univariable HR 2.06 (95% CI, 1.36–3.13; P = .001).

“EXPOSURES: Surgical resection with or without adjuvant chemotherapy.”
Claim 6 of 9SupportedNineteen patients (9.4%) experienced recurrence during a median follow-up of more than five years; recurrence occurred in 6% of stage 2 disease and 19.5% of stage 3 disease.View evidenceHide evidence

As stated9.4%

Why this verdict

The profile reports median follow-up of 62.6 months, 19 relapses among 202 surgical patients (9.4%), and stage-specific relapse rates of 6% for stage II and 19.5% for stage III.

1

Study evidence

Relapse after resection was uncommon in the institutional surgical subset (19 of 202; 9.4%); relapse rates by stage were 6% for stage II and 19.5% for stage III.9.4% overall relapse in surgical subset; stage II 6%; stage III 19.5%

“This retrospective cohort study (January 2000 through February 2024; median follow-up, 62.6 months) used Kaplan-Meier and Cox proportional hazards modeling.”
Claim 7 of 9SupportedPatients whose cancer returned had poorer outcomes, with a five-year overall survival rate of 77.2% compared with 95.7% among those who did not experience recurrence.View evidenceHide evidence

As stated77.2% vs 95.7%

Why this verdict

The profile reports five-year overall survival of 95.7% without relapse versus 77.2% with relapse, with relapse associated with higher mortality risk.

1

Study evidence

Relapse after resection was uncommon in the institutional surgical subset (19 of 202; 9.4%); relapse rates by stage were 6% for stage II and 19.5% for stage III.9.4% overall relapse in surgical subset; stage II 6%; stage III 19.5%

“This retrospective cohort study (January 2000 through February 2024; median follow-up, 62.6 months) used Kaplan-Meier and Cox proportional hazards modeling.”
Claim 8 of 9SupportedTP53 mutations were linked to recurrence in goblet cell tumors, while GNAS mutations were associated with higher relapse risk in non-goblet tumors.View evidenceHide evidence

Why this verdict

The profile reports subtype-specific genomic associations: TP53 mutation in goblet cell tumors and GNAS mutation in nongoblet tumors were associated with greater relapse risk.

1

Study evidence

Relapse after resection was uncommon in the institutional surgical subset (19 of 202; 9.4%); relapse rates by stage were 6% for stage II and 19.5% for stage III.9.4% overall relapse in surgical subset; stage II 6%; stage III 19.5%

“This retrospective cohort study (January 2000 through February 2024; median follow-up, 62.6 months) used Kaplan-Meier and Cox proportional hazards modeling.”
2

Study evidence

TP53 mutation in goblet cell tumors was associated with greater risk of relapse.HR 6.93 (95% CI, 1.50–31.00); P = .01

“TP53 mutation in goblet cell tumors… and GNAS mutation in nongoblet tumors… were associated with greater risk of relapse.”
Claim 9 of 9SupportedThe article notes limitations including that patients were treated at a single cancer center and that more research is needed to confirm the findings.View evidenceHide evidence

Why this verdict

The supplied profile supports that the main analysis was a retrospective institutional cohort centered at UT MD Anderson, with abstract-level limitations that make further confirmation important. However, the story's caveats are incomplete: it does not mention several interpretation-changing limitations such as retrospective nonrandomized treatment assignment, small event counts, unspecified covariates, chemotherapy-regimen details, or limited abstract-level validation information.

1

Study evidence

Relapse after resection was uncommon in the institutional surgical subset (19 of 202; 9.4%); relapse rates by stage were 6% for stage II and 19.5% for stage III.9.4% overall relapse in surgical subset; stage II 6%; stage III 19.5%

“This retrospective cohort study (January 2000 through February 2024; median follow-up, 62.6 months) used Kaplan-Meier and Cox proportional hazards modeling.”
2

Study evidence

In the complete localized cohort, adjuvant chemotherapy was not associated with improved recurrence-free survival after multivariable adjustment.Multivariable HR for RFS 0.98 (95% CI, 0.43–2.28; P = .90); Univariable HR 2.06 (95% CI, 1.36–3.13; P = .001).

“EXPOSURES: Surgical resection with or without adjuvant chemotherapy.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Small number of relapse events in the surgical subset—19 relapses among 202 patients—limits precision and subgroup analyses.

    The story reports the 19 events and 9.4% recurrence rate, but does not identify the small event count as a limitation affecting precision and subgroup reliability.

    From Retrospective cohort

7 things the story did carry across
  • Retrospective observational design using institutional records, Kaplan–Meier analysis, and Cox proportional hazards modeling rather than randomized treatment assignment.
  • Complete localized UT MD Anderson cohort included 439 stage I–III appendiceal adenocarcinoma patients from 2000–2024; surgical subset at MD Anderson included 202 patients.
  • Relapse after resection was uncommon in the institutional surgical subset: 19 of 202 patients, 9.4% overall, with 6% stage II and 19.5% stage III relapse rates.
  • Patients with relapse had worse overall survival: five-year OS 77.2% with relapse versus 95.7% without relapse.
  • Adjuvant chemotherapy was not associated with improved RFS or OS after multivariable adjustment in the complete localized cohort.
  • Clinicopathologic factors associated with relapse included mucinous and enteric-type histology versus goblet cell tumors, and pathologic T4 stage.
  • Selected genomic alterations were associated with relapse risk: TP53 mutation in goblet cell tumors and GNAS mutation in nongoblet tumors.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoIdentify clinicopathologic and genomic factors associated with relapse after resection of localized appendiceal adenocarcinoma (AA).Retrospective cohortExpand

In plain English

Retrospective cohort study of localized (stage I–III) appendiceal adenocarcinoma (AA) at UT MD Anderson (2000–2024; median follow-up 62.6 months) that used time-to-event analysis (Kaplan–Meier, Cox PH) to identify clinicopathologic and genomic factors associated with relapse after surgical resection. In the institutional surgical subset (n = 202) relapse was uncommon (19 events, 9.4% overall; 6% stage II, 19.5% stage III). Compared with goblet cell tumors, mucinous and enteric-type histologies and pathologic T4 were independently associated with higher relapse risk; several colorectal cancer risk features (poor differentiation, perforation, lymphovascular invasion, perineural invasion) were not associated with relapse. TP53 mutation in goblet cell tumors and GNAS mutation in non-goblet tumors were associated with increased relapse risk. A stage-II validation cohort from MSKCC is reported in the paper (abstract), and adjuvant chemotherapy analyses using the full localized cohort are reported but are outside the primary prognostic-factor focus of this appraisal unit.

Key findings

  • Relapse after resection was uncommon in the institutional surgical subset (19 of 202; 9.4%); relapse rates by stage were 6% for stage II and 19.5% for stage III.9.4% overall relapse in surgical subset; stage II 6%; stage III 19.5%
  • Mucinous and enteric-type histologies were independently associated with higher relapse risk compared with goblet cell tumors.Mucinous HR 5.60 (95% CI, 2.1–15); Enteric-type HR 6.60 (95% CI, 2.9–15)
“This retrospective cohort study (January 2000 through February 2024; median follow-up, 62.6 months) used Kaplan-Meier and Cox proportional hazards modeling.”
What this piece can’t prove
  • Retrospective cohort design (reported in abstract).
  • Small number of relapse events in the institutional surgical subset (19 relapses among 202 patients), limiting precision of effect estimates and subgroup analyses.

2 further details could not be confirmed from the summary.

2secondary dataIdentify clinicopathologic and genomic factors associated with relapse after resection of localized appendiceal adenocarcinoma (AA).retrospective cohort genomic associationExpand

In plain English

In a retrospective cohort of localized appendiceal adenocarcinoma, tumor molecular profiling identified subtype-specific gene–relapse associations: TP53 mutations in goblet cell tumors and GNAS mutations in non-goblet tumors were each associated with substantially higher risk of relapse (reported hazard ratios).

Key findings

  • TP53 mutation in goblet cell tumors was associated with greater risk of relapse.HR 6.93 (95% CI, 1.50–31.00); P = .01
  • GNAS mutation in nongoblet tumors was associated with greater risk of relapse.HR 17.0 (95% CI, 3.09–93.3); P = .001
“TP53 mutation in goblet cell tumors… and GNAS mutation in nongoblet tumors… were associated with greater risk of relapse.”
What this piece can’t prove
  • Findings are from a retrospective observational cohort; potential for unmeasured confounding.
  • Abstract does not indicate whether the specific gene–subtype associations (TP53 in goblet, GNAS in nongoblet) were externally validated.

1 further detail could not be confirmed from the summary.

3human in vivoAssess the efficacy (association with outcomes) of adjuvant chemotherapy after resection for localized AA.retrospective cohort comparative effectivenessExpand

In plain English

Retrospective comparative effectiveness analysis in a complete localized cohort of appendiceal adenocarcinoma evaluating association of adjuvant chemotherapy (vs no adjuvant chemotherapy) with recurrence-free survival (RFS) and overall survival (OS). Using Kaplan–Meier and Cox proportional hazards models (univariable and multivariable) in the UT MD Anderson cohort (patients 2000–2024; median follow-up 62.6 months; n for complete localized cohort reported as 439), adjuvant chemotherapy was not associated with improved RFS or OS after multivariable adjustment.

Key findings

  • In the complete localized cohort, adjuvant chemotherapy was not associated with improved recurrence-free survival after multivariable adjustment.Multivariable HR for RFS 0.98 (95% CI, 0.43–2.28; P = .90); Univariable HR 2.06 (95% CI, 1.36–3.13; P = .001).
  • In the complete localized cohort, adjuvant chemotherapy was not associated with improved overall survival after multivariable adjustment.Multivariable HR for OS 0.71 (95% CI, 0.24–2.1; P = .53); Univariable HR 1.80 (95% CI, 1.0–3.2; P = .04).
“EXPOSURES: Surgical resection with or without adjuvant chemotherapy.”
What this piece can’t prove
  • Retrospective observational design with nonrandomized treatment assignment — potential for residual confounding.
  • Abstract does not specify which covariates were included in multivariable models or the model-building approach.

3 further details could not be confirmed from the summary.

4human in vivoExternally validate relapse-risk findings in an independent cohort from MSKCC.retrospective external validation cohortExpand

In plain English

An independent external validation cohort from Memorial Sloan Kettering Cancer Center (MSKCC) comprising 128 patients with stage II appendiceal adenocarcinoma was included to validate relapse-risk findings from the primary MD Anderson cohort. The abstract reports inclusion of this validation cohort but does not present cohort-specific results or effect estimates.

Key findings

  • An external validation cohort from MSKCC of 128 stage II AA patients was included to validate relapse-risk findings from the MD Anderson cohort.
“...with validation from Memorial Sloan Kettering Cancer Center (MSKCC).”
What this piece can’t prove
  • Validation cohort limited to stage II disease (n=128), which may restrict generalizability of the validation to other stages.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 15 candidate papers

Candidate

Review: Adjuvant chemotherapy improves recurrence-free intervals and recurrence-free survival in soft-tissue sarcoma

Evidence Based Medicine · 1999 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.